Latest News and Press Releases

GVN calls on world governments to address the threat of H5N1 avian influenza by enhancing surveillance, implementing biosecurity measures, and preparing

Pre-clinical studies for intranasal RIG-101, a first in class RIG-I agonist, demonstrate potent local innate immune stimulation and pan-viral activity against human rhinovirus, influenza and RSV...

Ancilia raised $4.2M to leverage CRISPR’s natural function to create bacterial therapies with immunity against the viruses that limit their effectiveness.

Austin, TX, USA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Crop Protection Chemicals Market Size, Trends and Insights By Type (Herbicides,...

FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...

FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...

Program-Related Investment and Grant from the Bill & Melinda Gates Foundation to advance RIGImmune’s RNA therapeutics platform for influenza and pan-viral respiratory therapies Company also...

KNOXVILLE, TN, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene...

Hamilton, Bermuda, November 20, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Carson, CA, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Moleaer, a leading nanobubble technology company, in collaboration with Arizona State University’s (ASU) Research Center for Nanotechnology Enabled...